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Abstract
Background: Ras is frequently mutated in a variety of human cancers, including lung cancer, leading to constitutive
activation of MAPK signaling. Despite decades of research focused on the Ras oncogene, Ras-targeted phosphorylation
events and signaling pathways have not been described on a proteome-wide scale.
Methodology/Principal Findings: By functional phosphoproteomics, we studied the molecular mechanics of oncogenic Ras
signaling using a pathway-based approach. We identified Ras-regulated phosphorylation events (n=77) using label-free
comparative proteomics analysis of immortalized human bronchial epithelial cells with and without the expression of
oncogenic Ras. Many were newly identified as potential targets of the Ras signaling pathway. A majority (,60%) of the Ras-
targeted events consisted of a [pSer/Thr]-Pro motif, indicating the involvement of proline-directed kinases. By integrating
the phosphorylated signatures into the Pathway Interaction Database, we further inferred Ras-regulated pathways,
including MAPK signaling and other novel cascades, in governing diverse functions such as gene expression, apoptosis, cell
growth, and RNA processing. Comparisons of Ras-regulated phosphorylation events, pathways, and related kinases in lung
cancer-derived cells supported a role of oncogenic Ras signaling in lung adenocarcinoma A549 and H322 cells, but not in
large cell carcinoma H1299 cells.
Conclusions/Significance: This study reveals phosphorylation events, signaling networks, and molecular functions that are
regulated by oncogenic Ras. The results observed in this study may aid to extend our knowledge on Ras signaling in lung
cancer.
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Introduction
Constitutive activation of Ras-mediated signaling and its
downstream components, such as MAP family kinases, play an
important role in the pathogenesis of human cancers 1,2]. Lung
cancer represents a good choice for investigating the molecular
mechanisms of Ras-mediated MAPK signaling, because the
activation of Ras oncogenes by mutation or amplification has
been reported most frequently in lung cancer 1,3]. Among the
post-translational modifications, reversible protein phosphoryla-
tion is a dominant regulatory mechanism involved in the
oncogenic signaling process. Simultaneous identification and
quantification of phosphorylation events induced by oncogenic
signaling not only would provide insight into signaling mechanisms
but also are essential for understanding the molecular determi-
nants of disease progression. Despite decades of intensive analysis
of the Ras family of proto-oncogenes (HRAS, NRAS, and KRAS)
and corresponding biological processes 2,4], the downstream
phosphorylation targets and pathways regulated by oncogenic
Ras-mediated signaling remain to be elucidated in lung cancer.
Apart from traditional molecular biological approaches, alter-
native strategies are needed to identify downstream phosphoryla-
tion targets and regulated pathways of oncogenic signals.
Presently, quantitative phosphoproteomics is being widely used
and is emerging as a key technology in signal transduction
research 5]. The in vitro and in vivo incorporation of stable isotopes
into samples has been introduced and is extensively used 6,7].
However, the isotopic labeling-based quantitation limits the
analysis of a large number of samples in a single experiment.
Hence, label-free quantitation methods have gained more
popularity in recent years 8]. To gain further information on
Ras-regulated cellular processes, we conducted a pathway-based
investigation to evaluate Ras activity. We identified Ras-mediated
phosphorylation events in immortalized human bronchial epithe-
lial cells (HBECs) using IDEAL-Q (ID-based elution time
prediction by fragmental regression)-based quantitation proteo-
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signaling pathways and molecular functions. Furthermore, the
interpretation of Ras-mediated phosphorylation targets and
related pathways allowed us to demonstrate the involvement of
Ras-mediated signaling in lung adenocarcinoma (AD), but not in
large cell carcinoma (LCC). Our findings on the phosphorylation
events, kinomes, and pathways regulated by oncogenic Ras and
differential activation of Ras downstream signaling in lung AD and
LCC could serve as a basis for future investigations elucidating the
molecular mechanisms involved in the pathogenesis of human
cancers.
Methods
Cell culture
Cdk4 (cyclin-dependent kinase 4)/hTERT (human telomerase
reverse transcriptase)-immortalized human bronchial epithelial
cells (HBEC3-KT or 3KT) and K-RAS
V12-transformed HBEC3-
KT cells (3KTR) were maintained in K-CFM medium containing
50 mg/mL bovine pituitary extract (BPE) and 5 ng/mL EGF
under 5% CO2 and 37uC, as previously described 9,10]. These
cells were the kind gift of Dr. John D. Minna (University of
Southwestern Medical Center, Dallas, TX, USA). The human
non-small-cell lung cancer (NSCLC) H1299, H322, and A549 cell
lines were purchased from the American Type Culture Collection.
H1299 and H322 cells were grown in RPMI medium supple-
mented with 10% fetal bovine serum and 1% antibiotics under
tissue culture conditions. A549 cells were grown under similar
conditions in DMEM supplemented with 10% fetal bovine serum
and 1% antibiotics.
Knockdown experiments, lysis, western blot analysis,
tryptic digestion, and phosphopeptide enrichment
The lentivirus-based knockdown approach has been previously
described [11]. The pLKO.1-short hairpin RNA (shRNA)
plasmids encoding an shRNAs with sequences targeting the firefly
luciferase and with sequences targeting human KRAS (sh1:5 9-
CTATGGTCCTAGTAGGAAAT-39; and sh2:5 9-GAGGGCT-
TTCTTTGTGTATTT-39) purchased from the National RNAi
Core Facility, Taiwan, were introduced into HEK293T cells with
lentiviral packaging vectors pMD.G and pCMV 8.91. Viruses
were collected from the medium 60 h after transfection. For
knockdown experiments, cells were infected with the collected
viruses over 24 h in the presence of Polybrene (at 3 MOI for H322
and 5 MOI for A549 and H1299). Cells were cultured in
designated medium for 24 hr prior to lysis. To prepare cell lysates,
cells were grown to 85% confluence and subjected to lysis using
modified RIPA buffer containing 0.5% NP40 (Igepal CA-630),
300 mM NaCl, 1 mM EDTA, 0.5 mM DTT, 1 mM NaVO3,
10 mM NaF, and a cocktail of protease inhibitors (Roche,
Indianapolis, IN, USA). After centrifugation at 15,0006 g for
5 min, the cell lysates were collected. Western blotting was
performed as previously described [11]. Tube-gel digestion was
performed as previously described [12] with modifications.
Phosphopeptides were purified using a revised one-step IMAC
as previously described [13]. For more details, see Methods S1.
Mass spectrometry analysis and label-free quantitation
Purified phosphopeptide samples were desalted and analyzed by
LC-MS/MS (Waters Q-Tof Premier
TM; Waters Corp., Milford,
MA, USA). The MS was operated in ESI positive V mode with a
resolving power of 10,000. Data were acquired via Data Directed
Analysis (DDA). The method included a full sequential MS scan
(m/z 400–1600, 0.6 s) and 3 MS/MS (m/z 100–1990, 1.2 s per
scan) of the three most intense ions present in the full-scan mass
spectrum. The details of the MS analysis, peptide identification,
and label-free quantitation using the IDEAL-Q algorithm [14] are
available in Methods S1.
Calculation of pathway activity
Based on the report of Lee et al. [15], we developed a method to
infer the activity of individual signaling pathways by integrating
the levels of related phosphoprotein signatures determined by
proteomics analysis. For each pathway, the representative values
of phosphoproteins were summed, and the mean (Xi) and
standard deviation (ri) for each class (e.g., 3KT and 3KTR) were
defined. The pathway activity (ap) was derived using t-test statistics
to discriminate between two classes and formulated.
Pathway functional clustering
Pathways were clustered based on their functional similarity.
The functional similarity was computed for each pathway pair
based on the Gene Ontology (GO) annotations of proteins in each
pathway. The details of pathway functional clustering are available
in Methods S1 [16–18].
Results
Phosphopeptide profiling of HBECs and NSCLC cells
To study Ras-mediated downstream phosphorylation events
and Ras involvement in lung cancer, Cdk4/hTERT-immortalized
human bronchial epithelial cells (HBEC3-KT or 3KT) and
KRAS
V12-transformed 3KT (3KTR) cells were subjected to
quantitative phosphoproteomics analysis. Three non-small cell
lung cancer (NSCLC)-derived cell lines, A549 (adenocarcinoma,
AD), H322 (AD), and H1299 (large cell carcinoma, LCC), were
also studied. The flowchart in Figure 1 outlines the strategy
followed in this study. The phosphopeptides enriched from each
cell lysate were analyzed three times by LC-MS/MS. A total of
1645 phosphorylated peptides derived from 756 proteins were
identified across the cell lines. More than 80% of the phosphopep-
tides were identified in triplicate runs of each cell line (Figure S1A).
The abundances of phosphopeptides were shown less than 20%
coefficient of variation (CV) in triplicate runs (Figure S1B). For
quantitation, we first examined the abundance of the co-enriched
phosphopeptide (
49FQpSEEQQQTEDELQDK
63) from b-casein,
an internal standard, and it was consistent in the triplicate runs of
each cell lysate and comparable with those from other cell lysates,
demonstrating the efficiency of tryptic digestion and the IMAC
enrichment process (Figure S1C). Phosphopeptides were then
normalized using an internal standard and compared between the
transformed and normal cell lines (3KTR, A549, H322, or H1299
vs. 3KT) and among the three NSCLC cell lines (H1299 vs. A549
or H322, and A549 vs. H322) by means of the label-free IDEAL-
Q quantitation system. IDEAL-Q, a fully automated tool,
performs normalization and quantitation of comparable peptides
between parallel runs of unlimited samples [14]. The quantitative
comparison and normalization performed in the case of 3KTR vs.
3KT are shown in Figure S1D and S1E.
Of the phosphopeptides identified (n=1645), 1508 peptides
from 696 proteins were quantified based on their concurrent
detectability in the individual pairs of cell lines to be compared
(Figure 2A and Table S1). For any pair of cell lines, 70.3 to 85.4%
of the phosphopeptides were quantified, and for any cell line,
.95% of the phosphopeptides were quantified. In the case of
3KTR vs. 3KT, 1288 phosphopeptides were quantified, and most
(94%) displayed a relative expression ratio within twofold,
consistent with the isogenic background of these two cell lines.
Oncogenic Ras Signaling in Lung Adenocarcinoma
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vs. 3KT; A549 or H322 vs. H1299; and A549 vs. H322), more
regulated phosphorylation events (30.2–36.4%) were identified.
The regulated phosphosites were further sorted using motif-x [19].
This resulted in the identification of a proline-directed ([pS]-P)
motif as an over-represented species in the regulated phosphopep-
tides in Ras-transformed HBECs and NSCLC cells. Additional
basophilic (R-X-X-[pS]) and acidophilic ([pS]-[D/X]-X-[E/X])
motifs were also found in the NSCLC cells (Figure 2B).
Defined subsets of kinases are differentially activated in
Ras-transformed HBECs and NSCLC cells
Given that the regulated phosphopeptides consisted of motif
sequences with distinctive features, we further explored the
potential upstream kinases accountable for the regulated
phosphorylation events by NetworKIN analysis. The Networ-
KIN algorithm predicts in vivo kinase-substrate relationships
based on not only motif sequences but also various contextual
factors [20–22]. The site-specific upstream kinases of regulated
phosphorylation events identified by NetworKIN (Table S2)
were further arranged into four subgroups according to their
target motif sequences (Table S3 and Figure 3A). In Ras-
transformed HBECs, kinases targeting proline-directed phos-
phosites represented the major subset in the phosphorylation
network. A similar pattern was observed in AD cells (A549 and
H322), but not in LCC H1299 cells (Figure 3A). Through a
homogeneity test, the AD A549 and H322 cells appeared to
share an undistinguishable pattern of upstream kinomes
(p=0.716). In contrast, the LCC H1299 cells displayed a more
unique pattern, significantly different from that of the AD cells
(p,0.0001), in which subsets of basophilic kinases and proline-
directed kinases played equally important roles in the upstream
kinomes (Figure 3A).
Supporting the above observations, both the LC-MS/MS and
IDEAL-Q quantitative results and Western blot analysis showed
increased phosphorylation and activation of proline-directed
MAPK1 in Ras-transformed HBECs and AD cells, but not in
LCC cells (Figure S2 and Figure 3B). Furthermore, the
phosphorylation of PKN2, a basophilic kinase of the PKC family
[23], was shown by LC-MS/MS analysis to be downregulated in
AD cells, but not in LCC cells (Table S1, rows 427 and 428).
Other basophilic kinases such as AKT [21,24] have been reported
to be upregulated in H1299 cells relative to levels in several AD
cell lines, including A549 [25]. These data suggest that different
subsets of kinomes are differentially involved in the pathogenic
development of lung AD and LCC.
Figure 1. Schematic of the experimental design. Whole cell extracts were prepared from Cdk4/hTERT-immortalized human bronchial epithelial
cells (HBEC3-KT or 3KT), KRAS
V12-transformed 3KT (3KTR), and NSCLC A549, H322, and H1299 cells, then mixed with b-casein as an internal standard,
and subjected to trypsin digestion. Phosphopeptides were enriched from each cell extract using IMAC and analyzed three times by LC-MS/MS.
Peptides were identified by Mascot search, and phosphorylation changes were quantified in pairs across the five cell lines using the IDEAL-Q label-
free system. The interpretation of phosphoproteomics data was performed by means of in silico analysis. Mt, mutant; AD, adenocarcinoma; LCC, large
cell carcinoma; IMAC, immobilized metal affinity chromatography.
doi:10.1371/journal.pone.0020199.g001
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Ras signaling in HBECs and NSCLC cells
By quantitative proteomics, we identified 52 proteins that were
differentially phosphorylated at 77 sites in HBECs upon Ras-
transformation (Table S4). Many of these proteins are known as
downstream targets of MEK- or ERK-mediated signaling and
include MAPK1 (ERK2) (at T185 and Y187), MAPK3 (Y204),
cortactin (T364), FAM129B (S667), LMNA, MAP4, PAK4, and
SRRM2 [26,27]. Most importantly, many others were newly
identified as potential targets of the Ras signaling pathway (Table
S4). Western blot analyses were performed using site-specific
antibody available to recognize the phosphorylated motif of lamin
serine 392. In agreement with the mass spectrometric data,
western blot showed upregulated phosphorylation of lamin at
serine 392 in 3KTR relative to 3KT cells (Figure 3C), which is in
agreement with the mass spectrometric data (Table 1). Attempts
were also made to examine the phosphorylation status of cortactin
by immunoprecipitating cortactin in cell lysates followed by
immunobloting using antibody recognizing phosphorylated Ser/
Thr residues. Although we can not pinpoint the phosphorylation
of cortactin at threonine 364 residue, our data showed the
upregulation of cortactin phosphorylation in 3KTR cells relative
to 3KT (Figure 3C) (Table 1). Further, we performed the KRAS-
knockdown experiments using Lentivirus-based approach to
characterize the lamin pS392 status in three non-small cell lung
cancer cells (A549, H322 and H1299) cultured in serum-free
condition (Figure 3D). Introduction of two independent KRAS-
shRNAs led to a significant decrease in the expression of KRAS
protein in comparison to that of the control shRNA targeting at
luciferase mRNA. In addition, knockdown of KRAS resulted in
downregulation of lamin pS392 in adenocarcinoma A549 and
H322 cells but not in large cell carcinoma H1299 cells. These
results are in agreement with the mass spectrometry data, where
we observed the upregulated lamin pS392 in A549 and H322 and
but not in H1299 (Table 1).
Examination of the 52 Ras downstream phosphoproteins with
the Panther Classification System revealed that most were
involved in cell structure and motility, nucleic acid metabolism,
cell cycle, signal transduction, or apoptosis according to their
molecular function (Figure S3A) and biological process (Figure
S3B). As Ras activation is a frequent event in lung adenocarci-
noma [1,3], we next looked at the status of Ras-regulated
phosphorylation events in the three NSCLC cell lines. In
agreement with the observation of enhanced MAPK activation
in AD cells, but not in LCC cells, about 50% of the Ras-
upregulated proline-directed sites (n=31) were upregulated in AD
cells (A549 and H322), whereas only 6% were upregulated in LCC
cells (H1299) (Figure 3E and Table S4). Among the 52 Ras-
regulated proteins, 14 were concurrently found to be regulated in
AD A549 and H322 cells, but not in LCC H1299 cells (Table 1).
Figure 2. Motifs or consensus sequences of regulated phosphorylation events identified in Ras-transformed HBECs and NSCLC
cells. (A) The numbers of comparable phosphopeptides subjected to quantitative proteomics analysis and the upregulated and downregulated
phosphopeptides identified in each pair of cell lines are shown. (B) Representative motif sequences were extracted from the regulated
phosphopeptides using motif-x. The motifs with significance of p,10
210 are shown.
doi:10.1371/journal.pone.0020199.g002
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pathways in the pathogenic development of lung AD.
Identification of Ras-regulated pathways in HBECs and
their involvement in lung AD, but not LCC
Our data showed that Ras-regulated phosphorylation events are
conserved in AD cells, and thus we further inferred the activation
status of pathways, including MAPK signaling, in these cells by
integrating the levels of the regulated phosphorylation events into
individual signaling pathways according to the NCI-Nature
Pathway Interaction Database (PID). For each signaling pathway,
an activity level was summarized from the phosphorylation levels
of the subset of proteins in the pathway, following the method
reported by Lee et al. with modifications [15]. Figure 4A shows a
schematic representation and equations for the pathway activity
analysis. Pathways were included in the activity analysis only when
they consisted of five or more identified phosphoproteins. The
pathway activity signatures identified in each pair of cell lines are
listed in Table S5. We observed 23 upregulated and two
downregulated pathways downstream of oncogenic Ras in
HBECs. The upregulated pathways included growth factor-
mediated signaling pathways from HGF, FGF, and VEGF. The
computation of pathway activities revealed the upregulation of
proline-directed kinase MAPK signaling in 3KTR and AD cells
(A549 and H322), but not in LCC H1299 cells (Figure 4B). In
contrast, higher activity of the basophilic kinase Aurora B-
mediated signaling pathway was observed in H1299 cells
compared with A549 and H322 cells (Figure 4B).
In the subgroup of upstream kinases targeting proline-directed
sites, the MAPK family represented the major upstream species,
followed by CDK and GSK (Table S3). The subgroup of kinases
targeting basophilic phosphosites included PAK, PKC, DMPK,
CLK, Pim, PKA, and PKB. Unlike the pattern of kinases
upstream of the regulated phosphorylation events in the Ras-
transformed HBECs and AD cells, a higher percentage of
basophilic kinases was observed in the LCC H1299 cells
Figure 3. Characterization of the differentially phosphorylated events in Ras-transformed HBECs and NSCLC cells. (A) The kinases
targeting regulated phosphosites were derived using NetworKIN analysis. According to their target sequences, the upstream kinases were grouped
into subsets of proline-directed, basophilic, acidophilic, and other kinases. Their frequencies are shown for each cell line. (B) Western blot analysis of
ERK activation in HBECs and NSCLC cells. (C) Phosphorylation of lamin-A/C and cortactin in HBECs. Western blot analysis was performed to examine
the phosphorylation of lamin-A/C at S392 using site-specific antibody. Phosphorylation of cortactin (CTTN) was determined by immunoprecipitation
of cortactin in cell lysates using anti-cortactin antibody followed by immunoblot analysis using antibody specific for phosphorylated Ser/Thr. (D)
Western blot analysis of lamin-A/C phosphorylation in KRAS knockdown NSCLC cell lines. Lung cancer A549, H322 and H1299 cells were infected with
Lentivirus harboring shRNAs targeting at luciferase or KRAS overnight. Two individual shRNAs targeting at KRAS were employed. Cells were grown in
serum-free medium for an additional 24 hrs prior to western blot analysis of designated proteins. The status of lamin-A/C pS392 was detected by site-
specific antibody. b-actin was used as protein loading control. (E) Ras-regulated phosphorylation events observed in Ras-transformed HBECs and
NSCLC cells. The Ras-regulated phosphorylation events, including 49 upregulated and 28 downregulated events, identified in Ras-transformed HBECs
were classified as proline-directed and non-proline-directed phosphosites according to their consensus sequences. The conservation of Ras-regulated
phosphorylation events in NSCLC A549, H322, and H1299 cells is shown.
doi:10.1371/journal.pone.0020199.g003
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over-activated in H1299 cells were directly or indirectly linked to
the Ras/Raf/MAPK pathway (Figure 4C), suggesting that the
interplay between the Ras/Raf/MAPK signaling axis and
basophilic kinases may dominate the pathogenic development of
NSCLC.
Identification and functional significance of Ras
signaling-regulated phosphoproteins and pathways
We next established protein interaction networks to identify the
physical and functional interactions among the proteins that are
phosphorylated by Ras-mediated signaling. The proteins (n=584)
harboring the phosphopeptides (n=1288) that were subjected to
comparative proteomics analysis between normal HBECs and
Ras-transformed HBECs were further analyzed using the Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING)
database of physical and functional interactions. This yielded a
phosphoprotein interaction network consisting of 1279 known plus
predicted protein interactions among 401 proteins (Figure S4). In
this protein interaction network, we identified 45 proteins that
were previously described as direct targets of MAP kinase [28].
Most importantly, 40 of the 52 Ras-regulated phosphoproteins
identified in this study were found in the protein interaction
network (Figure S4). The establishment of a protein-protein
interactome suggests that downstream phosphorylation targets of
oncogenic Ras/MAPK-mediated signaling are closely associated
in their molecular function.
In a large-scale proteomics study, identifying kinase substrates is
difficult owing to the unavailability of antibodies. The NetworKIN
algorithm provides a highly accurate alternative approach for the
prediction of site-specific upstream kinases [20-22]. Among the 40
Ras-regulated proteins found in the protein interaction network,
14 were identified by NetworKIN analysis as novel substrates for
MAP kinases (Figure S4 and Table S4). Of the newly identified
MAPK target sites, COBRA1 (S557), LMNA (S392), LMO7
(S1259), and WRNIP1 (S153) represent bona fide targets of
MAPKs with high substrate specificity (Table S2). In the case of
LMNA, our study specifically revealed its enzyme activation site
(S392) as the target of oncogenic Ras-mediated MAP kinase
signaling. To further exclude the possibility that the regulated
phosphorylation resulted from differential expression of these
proteins, we analyzed the expression status of the corresponding
genes in a microarray dataset (NCBI’s GEO database, Reference
GSE11969) related to clinical samples, where normal lung (n=5)
Table 1. Identification of oncogenic Ras-regulated phosphorylation events that are concurrently regulated in adenocarcinoma
A549 and H322 cells, but not in large cell carcinoma H1299 cells.
Gene symbol Protein name
Swiss-Prot
ID Peptide sequence Site Log2 Ratio
3KTR/
3KT
A549/
3KT
H322/
3KT
H1299/
3KT
Ras stimulated phosphorylation events
BAT3 Large proline-rich
protein BAT3
P46379 APPQTHLPSGASSGTGSASA THGGGpSPPGTR S113 1.718 1.680 2.423 0.806
APPQTHLPSGASSGTGpSASA THGGGSPPGTR S104 1.717 1.664 2.400 0.776
APPQTHLPSGASSGTGSASA pTHGGGSPPGTR T108 1.715 1.679 2.420 0.803
BCLAF1 Bcl-2-associated
transcription factor 1
Q9NYF8 SSATSGDIWPGLSAYDNpSPR S222 1.104 1.612 1.176 0.688
SSATSGDIWPGLpSAYDNSPR S217 1.098 1.612 1.176 0.688
COBRA1 Negative elongation
factor B
Q8WX92 KPSPAQAAEpTPALELPLPSV PAPAPL T564 1.593 1.540 1.829 0.514
KPpSPAQAAETPALELPLPSV PAPAPL S557 1.589 1.531 1.827 0.477
CTTN Cortactin Q8N707 TQpTPPVSPAPQPTEER T364 1.065 1.052 1.236 21.680
FAM129B Niban-like protein Q96TA1 AAPEASpSPPASPLQHLLPGK S679 2.107 1.752 1.556 29999
LMNA Lamin-A/C P02545 LSPpSPTSQR S392 1.737 1.102 1.475 0.977
LpSPSPTSQR S390 1.193 1.098 1.084 0.975
MAPK1 MAP Kinase, ERK2 P28482 VADPDHDHTGFLTEpYVATR Y187 1.946 1.024 1.599 21.308
MICAL1 Calponin and LIM domain
containing 1
Q8TDZ2 LSpSPERQR S829 1.737 1.108 1.220 0.972
PPP1R13L RelA-associated inhibitor Q8WUF5 SESAPTLHPYSPLpSPK S113 1.218 1.235 1.688 0.532
SRRM2 Serine/arginine
repetitive matrix protein 2
Q9UQ35 SRpTPPSAPSQSR T2409 1.361 1.838 1.460 0.623
Ras repressed phosphorylation events
ABI1 Abl interactor 1 Q8IZP0 LGSQHpSPGR S225 21.184 21.181 21.932 20.669
API5 Apoptosis inhibitor 5 Q9BZZ5 RASEDTTSGpSPPKK S464 21.704 23.756 23.442 0.429
PALLD Palladin Q8WX93 pSPSGHPHVR S880 21.017 21.676 21.510 20.586
TMEM40 Transmembrane protein 40 Q8WWA1 RGpSDPASGEVEASQLR S153 21.293 25.644 22.08 29999
The regulated phosphorylation events are shown in Log2 scale. The relative phosphorylation levels with a 2-fold increase or decrease are indicated by bold font. The
protein symbol, full name, and Swiss-Prot database protein accession number corresponding to each phosphopeptide, along with the phosphorylated residue location,
are shown. ‘‘-9999’’ indicates peptides found in 3KT, but not in H1299.
doi:10.1371/journal.pone.0020199.t001
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KRAS mutations were compared. These genes were expressed at
comparable levels in lung carcinomas irrespective of the status of
KRAS mutations (Table S6). These data suggest that oncogenic
Ras-mediated MAPK signaling is involved in the elevated
phosphorylation of these bona fide target proteins.
Figure 4. Inferring pathway activity in Ras-transformed HBECs and NSCLC cells. (A) The levels of regulated phosphoprotein signatures
obtained from quantitative proteomics analysis were subjected to pathway activity analysis. Equations for summarizing the levels of phosphorylated
proteins and for analyzing pathway activity are shown. xi,j and ri,j are the mean and standard deviation, respectively, of the value of the
phosphoprotein j in class i, and k is the number of proteins in a given pathway. ap is the activity score for pathway p between classes c1 and c2, and
nc1 and nc2 are the numbers of replicate experiments for the respective classes. In our case, nc1 and nc2are each 3. (B) Inferred activities of MAPK and
Aurora B signaling pathways in Ras-transformed HBECs and NSCLC cells in comparison with HBEC-3KT are shown as relative pathway activity scores
(t-scores). (C) The involvement of the Ras/Raf/MEK/MAPK signaling pathway and its cross-talk with basophilic kinases in NSCLC cells. Kinases identified
as being upstream of the regulated phosphosites by NetworKIN analysis in this study are highlighted in bold font. Kinases targeting proline-directed
and basophilic S/T sites are labeled in green and blue letters, respectively. The frequencies of the individual kinases identified in A549, H322, and
H1299 cells in comparison with HBEC-3KT are shown in parentheses.
doi:10.1371/journal.pone.0020199.g004
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based on their biological processes and function similarities. Figure
S5 shows the hierarchical clustering analysis of the 23 signaling
pathways regulated by oncogenic Ras. A heat map was generated to
show the functional associations among the pathways according to
functional similarity scores ranging from 1.0 to 0.06. We identified
four clusters of tightly associated pathways with high similarity
($0.5) among the Ras-activated signaling pathways (Figure S5).
The clusters represented the regulation of RNA processing,
apoptosis, cell growth, and gene expression, respectively. Moreover,
pathways associated with MAP kinase signaling were identified with
a half-maximum functional similarity score ($0.5) as a threshold. In
addition to the HGF-mediated signaling pathway (functional
similarity score of 0.505), others, including the BCR (0.548),
keratinocyte receptor (0.52), agrin (0.493), and Fc-epsilon receptor
(0.492) pathways, were inferred in this study as novel pathways
associated withRas/MAPkinasesignaling (TableS7).Theresults of
the pathways associated with oncogenic Ras signaling correspond
well to previously described molecular functions of Ras signaling
[3,4,29]. In contrast, the downregulated pathways observed in Ras-
transformed HBECs did not show any association.
Discussion
Using mass spectrometry-based comparative phosphoproteo-
mics, we established the phosphorylation profiles of five lung
epithelial cell lines. Comparison of HBECs upon Ras-transforma-
tion revealed that proline-directed kinases, which include the
MAPK family, are the major mediators of Ras downstream
signaling. The comparisons of the upstream kinases in three
NSCLC cell lines demonstrated that proline-directed and
basophilic kinases play important roles in the regulation of
phosphorylation events in AD and LCC cells. Further, we inferred
Ras-regulated pathways and their functions by introducing an
algorithm, which supports the stimulation of Ras/MAPK signaling
in lung adenocarcinoma but not in LCC. Our data demonstrate
Ras-regulated phosphorylation events and pathways, as well as the
upstream kinomes, and thereby provide new insights into Ras-
mediated signaling networks in lung adenocarcinoma.
Quantitative comparisons of phosphopeptides across five cell
lines were performed using the IDEAL-Q system. For any cell line,
.95% of the phosphopeptides were quantified in the other four
cell lines, which is higher than previously reported, where only
63% of the identified peptides of the five samples were shown
using label-free quantitation 8]. The improved sensitivity of label-
free quantitation shown here is adaptable to any system analyzing
multiple samples. In our study, the number of regulated
phosphorylation events was much lower in the comparison of
3KT and 3KTR cells (Figure 2A). This is consistent with the
nature of their isogenic background and further demonstrates the
usefulness of the immortalized HBECs in studying the phospho-
proteomic profiles of oncogenic signaling 6]. A majority of the
Ras-regulated phosphosites identified in HBECs consisted of
proline-directed sequences. More than 50% of these proline-
directed phosphosites were upregulated in adenocarcinoma A549
(harboring the KRAS
G12D mutation) and H322 (KRAS amplifica-
tion) cells, but not in LCC H1299 (NRAS
Q61K) cells (Figure 3E and
Table 1), in agreement with previous reports that oncogenic
KRAS, but not oncogenic NRAS, is effective in stimulating
downstream MAPK signaling 30,31]. In addition, the upregula-
tion and downregulation of MAPK phosphorylation were
observed in AD and LCC cells, respectively, by LC-MS/MS
analysis (Figure S2) and immunoblotting (Figure 3B). In the
NetworKIN analysis, we showed that the involvement of basal
kinases including CAMKII, PKA, AKT/PKB, PKC, PAK, and
p70S6K was significantly increased in H1299 cells relative to A549
and H322 cells (Figure 3A). The increase in basophilic kinases may
lead to the attenuation of Ras-mediated MAPK signaling output in
H1299 cells (Figure 4C). Our data suggested that MEK/MAPK
kinases in adenocarcinoma cells where as downstream kinases of
PI3K and PLC including AKT/PKB, p70S6K and PKC in large
cell carcinoma cells play key roles in regulating the protein
phosphorylation events (Figure 4C).
Seventy-seven phosphorylation events in 52 proteins were
significantly altered by oncogenic Ras signaling in HBECs.
Among these proteins, 14 were identified as novel targets of
MAPK family kinases by NetworKIN analysis (Figure S4). These
proteins are involved in diverse biological processes and molecular
functions, including cytoskeletal organization (ABI1, KRT5,
LMO7, and MICAL1); nucleoskeletal organization (LMNA);
small GTPase-mediated signal transduction (SIPA1L1); ubiqui-
tin-involved signal transduction (UBAP2L); regulation of ubiqui-
tination (STUB1), acetylation processes (BAT3), DNA replication
(MCM2), and chromatin de-condensation and DNA synthesis
(WRNIP1); and negative regulation of transcription elongation
(COBRA1). NetworKIN analysis specifically revealed COBRA1
(S557), LMNA (S392), LMO7 (S1259), and WRNIP1 (S153) as
the site-specific phosphorylation targets of MAPK with relatively
high probability (Table S2). Among these, COBRA1 and LMNA
were upregulated in 3KTR, A549, and H322 cells, but not in
H1299 cells (Table S4). However, the upregulation of LMO7 was
observed in 3KTR, A549, H322, and H1299 cells. The regulated
phosphopeptide of LMO7 contains the sequence motif R-X-X-
[pS]-P, suggesting that an unknown basophilic kinase may be
involved in its regulation (Table S4). WRNIP1 was downregulated
in 3KTR cells, but upregulated in H1299 cells (Table S4). In this
study, residue S392 of LMNA, which is located at the enzyme
active site, was identified as a novel site-specific target of oncogenic
Ras-mediated MAPK signaling. The downregulation of WRNIP1
phosphorylation levels suggests cross-talk between oncogenic Ras
signaling and other pathways in controlling biological processes
through negative regulation of protein phosphorylation.
Understanding altered signaling pathways that regulate cellular
processes is a basis for drug discovery 32]. The identification of
deregulated pathways, rather than genes, as biomarkers would
give precise information of clinical value. Several studies have
demonstrated pathway signatures based on the transcriptome,
transcription factors, or proteome 33,34]. Given that phosphor-
ylation plays a major role in regulating signaling pathways that
dominate the pathogenic development of malignancies, we
demonstrated a new strategy to identify pathways altered at the
phosphorylation level. We inferred pathway activities, which
revealed the activation of MAPK signaling in Ras-transformed
HBECs. We further showed that MAPK signaling was upregu-
lated in A549 and H322 cells, but not in H1299 cells (Figure 4B).
These results are consistent with previous reports of mutations and
amplifications of KRAS leading to activation of downstream
signaling in lung adenocarcinomas 3]. Clustering the upregulated
pathways identified in Ras-transformed HBECs revealed that
molecular functions such as RNA processing, apoptosis, cell
growth, and gene expression are regulated by oncogenic Ras
signaling. Pathway correlation was performed for MAPK
signaling, and correlated pathways, including the agrin pathway,
BCR pathway, Fc-epsilon receptor pathway, HGFR signaling, and
keratinocyte pathway, were identified using a correlation threshold
of 0.5 (Figure S5). These findings unravel known and previously
unknown pathways and biological processes that are closely
associated with oncogenic Ras-mediated signaling.
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Figure S1 Identification of phosphopeptides, coefficient
of variation (CV) of phosphopeptide abundances, and
normalization process. (A) Whole cell lysates were prepared
from each cell line, mixed with b-casein, digested by trypsin, and
phosphopeptides were enriched by IMAC. The enriched phos-
phopeptides from each cell line was analyzed by LC-MS/MS for
three times. % of identified phosphopeptides in triplicate runs is
shown. (B) % of CV of quantifiable phosphopeptide abundances in
three runs are shown for five cell lines. (C) The observed
abundance of phosphopeptide (
49FQpSEEQQQTEDELQDK
63)
derived from b-casein in three LC-MS/MS runs is shown for five
cell lines. (D) Normalization process is shown for a case
comparison, 3KTR vs 3KT. Phosphopeptide ratios (in Log2 scale)
were obtained in the comparison of 3KTR and 3KT cells after
normalized against b-casein, internal standard intensity. The
phosphopeptide ratios are shown on X-axis and the number of
phosphopeptides is shown on Y-axis. (E) The ratios normalized
with internal standard were then log-centered.
(TIF)
Figure S2 MAPK phosphorylation observed by LC-MS/
MS. Quantitative assessment of the relative phosphorylation status
of ERK at T185 and Y187 residues in 3KTR, A549, H322, and
H1299 cells in comparison to 3KT cells by LC-MS/MS and
IDEAL-Q.
(TIF)
Figure S3 (A) Classification of Ras-regulated phosphoproteins
according to their molecular function. (B) Classification of Ras-
regulated phosphoproteins according to their biological processes.
The classification was made using the database, Panther
Classification System, available on http://www.pantherdb.org/.
(TIF)
Figure S4 Functional interaction network of the phos-
phoproteins in Ras-transformed HBECs. Phosphoproteins
identified in Ras-transformed HBECs were subjected to STRING
database with medium confidence ($0.4) applied. The upregu-
lated and downregulated phosphoproteins involved in oncogenic
Ras signaling are marked in pink and green boxes, respectively.
The known and novel substrates of MAP kinases identified by
NetworKIN analysis are marked in boxes circumscribed by blue
and red, respectively.
(TIF)
Figure S5 Clustering of Ras-regulated signaling path-
ways. Hierarchical agglomerative average-linkage clustering
analysis of oncogenic Ras-regulated pathways identified in HBECs
was performed based on their gene ontology functional similarity.
Pearson’s correlation coefficient was derived as the distance matrix
and visualized by Generalized Association Plots (GAP). The color
bar indicates the increasing association among the pathways with
increasing color intensity from blue to red. The rows and columns
show the pathways in similar order, and the association between
two identical pathways is shown as a red line throughout the map.
Four pathway clusters were identified, depicted in thick red lines
on the right side, using a correlation threshold of 0.5.
(TIF)
Table S1 The list of quantifiable phosphopeptides
across five cell lines are shown here. Upon comparisons,
phosphopeptides showing up- and down-regulated levels are
highlighted in red and green colors, respectively. Data corre-
sponding to each peptide identified by mass spectrometry and
Mascot search, including peptide sequence, m/z value, charge,
modification site, international protein index (IPI) accession
number, average abundance and standard deviation, are shown.
Few peptides were not quantified by IDEAL-Q and such peptides
are indicated as NaN, -9999, and 9999. In the case of 3KTR vs
3KT, if the peptide was not identified in both cell lines or
identified in 3KTR only or identified in 3KT only then they are
indicated as NaN, 9999 and -9999, respectively.
(XLS)
Table S2 The list of site specific upstream kinases of
regulated phosphorylation events predicted by Networ-
KIN. The regulated phosphorylated peptides identified in the
cases of 3KTR or A549 or H322 or H1299 vs 3KT were subjected
to NetworKIN analysis. List of site specific upstream kinases
predicted by NetworKIN analysis are shown in this table. For each
regulated peptide, Swiss-Prot accession number of the protein,
phosphorylation site, upstream kinase family, kinase ID, kinase
symbol, NetPhorest posterior probability, String score, Networ-
KIN score of the kinase, are shown.
(XLS)
Table S3 Frequency of upstream kinases of regulated
phosphorylation events identified in 3KTR, A549, H322
and H1299 cells. The upstream kinases of regulated phosphor-
ylation events identified in individual pairs of cell lines were
predicted by NetworKIN analysis. According to their target
sequences, the upstream kinases were grouped into subsets of
proline-directed, basophilic, acidophilic, and other kinases. The
kinases targeting other than proline-directed, basophilic and
acidophilic S/T sites are shown. The frequencies of subsets of
kinases are listed.
(XLS)
Table S4 The oncogenic Ras-regulated phosphorylation
events were identified in 3KTR and their status is shown
in NSCLC cells. The regulated phosphorylation events in
HBECs upon oncogenic Ras-transformation (3KTR vs 3KT) are
shown in Log2 scale. The relative levels of these phosphorylation
events in NSCLC cells (A549 or H322 or H1299 vs 3KT) in
relation to 3KT are shown. The regulated phosphosites were listed
as proline-directed, basophilic, acidophilic and others. The relative
phosphorylation levels with 2-fold increase or decrease are
indicated by bold font. Few peptides were not quantified by
IDEAL-Q and such peptides were indicated as NaN, -9999, and
9999. In the case of 3KTR vs 3KT, if the peptide was not
identified in both cell lines or identified in 3KTR only or identified
in 3KT only then they were indicated as NaN, 9999 and -9999,
respectively. The protein symbol, full name, and Swiss-Port
database protein accession number corresponding to each
phosphopeptide, along with phosphorylated residue location,
and NetworKIN assessment of upstream kinases are shown. In
the table, (A) indicates peptides listed here only when they
regulated in 3KTR in relation to 3KT with exception for MAPK1
T185, MAPK3 Y204 and MAPK14 Y182 peptides. (B) indicates
MEK1/2 kinases were not covered by NetworKIN. (C) indicates
MAP kinases are listed for the regulated sites according to the
NetworKIN specificity. (I) indicates isoform.
(XLS)
Table S5 The list of pathway activities inferred in Ras-
transformed HBECs and NSCLCs. The expression values of
up- and down-regulated phosphorylation events were integrated in
Pathway Interaction Database to examine the up- and down-
regulated pathway activity signatures respectively. Pathway
activities observed in four comparisons (3KTR or A549 or H322
or H1299 vs 3KT) were listed. For each identified regulated
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number of regulated phosphoproteins identified, pathway activity
score, are shown. The pathways consisting more than five
identified phosphoproteins were considered for pathway activity
analysis.
(XLS)
Table S6 The expression levels of bonafide MAPK
targets and MAP kinases in lung adenocarcinomas with
and without KRAS mutations. The relative expression levels
of bonafied MAPK targets and MAP kinases are shown by
comparing lung adeoncarcinomas with (n=12) and without
(n=84) KRAS mutations to normal tissues (n=5). This data is
derived from Agilent Homo sapiens 21.6K custom array, the data
values were corrected for background and normalized, and the
data was deposited on NCBI’s GEO oligo microarray database
(Data series GSE11969). Upon comparisons, proteins showing up-
and down-regulated levels are highlighted in red and green colors,
respectively.
(XLS)
Table S7 Identification of pathways associated with
Ras-signaling by pathway clustering. Upregulated pathways
(n=23) identified in Ras-transformed HBECs in relation to
normal HBECs (3KTR vs 3KT) were clustered based on their
gene ontology functional similarities. Correlation values observed
among the upregulated pathways in Ras-transformed HBECs are
shown. The maximum correlation score was one, which is seen
between the same pathways. The rows and columns show the
pathways in similar order therefore association between two
identical pathways shown a red line throughout the map (see
Figure S5).
(XLS)
Methods S1 Supplementary Methods.
(DOC)
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